# OnCo record idecabtagene-vicleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/idecabtagene-vicleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "idecabtagene-vicleucel" ;
  schema:name "Idecabtagene vicleucel"@en ;
  schema:description "Idecabtagene vicleucel was the first myeloma CAR-T (2021) and is now approved after two prior lines based on KarMMa-3."@en ;
  schema:url <https://onco.cc/drugs/idecabtagene-vicleucel/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Idecabtagene_vicleucel> ;
  owl:sameAs <http://www.wikidata.org/entity/Q106293994> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Idecabtagene%20vicleucel> ;
  onco:status "approved" ;
  onco:modality "CAR-T (BCMA)" ;
  schema:alternateName "Abecma" ;
  onco:approval "US 2021: Relapsed/refractory myeloma after ≥4 lines", "US 2024: After ≥2 lines including IMiD, PI, and anti-CD38" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/crossover/> ;
  onco:trials <https://onco.cc/trials/karmma-3/>, <https://onco.cc/trials/nct06045806/> .